Previous 10 | Next 10 |
2023-06-21 08:27:37 ET Greenpro Capital ( GRNQ ) +12% . Chemomab Therapeutics ( CMMB ) +14% Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023. PureCycle Technologies ( PCT ) +15% s...
WOBURN, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted presentation of new clinical data at the Diabetes UK meeting held April 23-26 in Liverpool, UK. The scientific poster was titled "Abnormal combined diabetic peripheral neuropathy (DPN)-check and SUDOSCAN resul...
WOBURN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted publication of an abstract describing partial results from a NIH-funded, multi-site randomized controlled trial of Quell titled "Wireless transcutaneous electric nerve stimulation (TENS) for chemotherapy-induce...
2023-05-03 13:05:45 ET Gainers: ImmunoGen ( IMGN ) +124% . GD Culture Group Limited ( GDC ) +115% . Aptorum Group Limited ( APM ) +92% . Aceragen ( ACGN ) +77% . NantHealth ( NH ) +57% . Sentage Holdings ( SNTG ) +61% ...
2023-05-03 12:41:02 ET NeuroMetrix, Inc. (NURO) Q1 2023 Earnings Conference Call May 03, 2023, 08:00 ET Company Participants Thomas Higgins - SVP, CFO & Treasurer Shai Gozani - Founder, Chairman, CEO, President & Secretary Conference Call Participants ...
2023-05-03 10:01:41 ET Gainers: Aptorum ( APM ) +133% . ImmunoGen ( IMGN ) +123% . Akanda ( AKAN ) +63% . Mersana Therapeutics ( MRSN ) +37% . CNS Pharmaceuticals ( CNSP ) +25% . Losers: Assure ( IONM ) -38% ....
2023-05-03 07:24:25 ET NeuroMetrix press release ( NASDAQ: NURO ): Q1 GAAP EPS of -$0.20. Revenue of $1.7M (-26.1% Y/Y). Gross profit in Q1 2023 was $1.2 million, a decrease of $0.6 million from the first quarter of 2022. The Q1 2023 gross margin rate contracted t...
WOBURN, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2023. The Company’s mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on populatio...
WOBURN, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2023 first quarter financial results before the opening of the market on May 3, 2023. The Company will host a conference call at 8:00 a.m., Eastern Time on May 3, 2023 to ...
WOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39 th Annual Meeting on March 23 - 26 in Ft. Lauderdale, FL. In addition, two scientific posters reporting new data on the use of Quell i...
News, Short Squeeze, Breakout and More Instantly...
WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2024. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medica...
Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...